×
About 2,902 results

ALLMedicine™ Biliary Tract Cancer Center

Research & Reviews  1,389 results

Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tr...
https://doi.org/10.1007/s10637-021-01098-2 10.1002/cncr.32803 10.1056/NEJMoa0908721 10.1038/sj.bjc.6605779 10.1002/jhbp.233 10.1007/s00280-007-0673-7 10.1007/s00280-013-2106-0 10.1007/s10637-010-9553-9 10.1093/jjco/hys102 10.1159/000226214 10.1038/bmt.2012.244 10.1038/sj.bjc.6603648 10.1093/jjco/hym116 10.1093/annonc/mdy282 10.1093/annonc/mdz402 10.1016/S1470-2045(19)30733-8
Investigational New Drugs; Inoue H, Todaka A et. al.

Apr 9th, 2021 - Background Combination therapy of gemcitabine with cisplatin (GC) is a standard first-line therapy for unresectable or recurrent biliary tract cancer (BTC). S-1 is often used as a second-line therapy in clinical practice, based on the results of s...

Comparison of Inflammation-based Prognostic Scores in Patients With Biliary Tract Cance...
https://doi.org/10.21873/anticanres.14987
Anticancer Research; Utsumi M, Kitada K et. al.

Apr 4th, 2021 - Inflammation-based prognostic scores are proven prognostic biomarkers in various cancers. This study aimed to identify a useful prognostic score for patients with biliary tract cancer (BTC) after surgical resection. This retrospective study recrui...

Prognosis of Primary Sclerosing Cholangitis According to Age of Onset.
https://doi.org/10.1002/jhbp.952
Journal of Hepato-biliary-pancreatic Sciences; Watanabe T, Nakai Y et. al.

Apr 3rd, 2021 - Liver failure and biliary tract cancer (BTC) are major life-threatening events in the clinical course of primary sclerosing cholangitis (PSC). Although these are competing events, they are typically evaluated as a composite prognostic endpoint. In...

Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary trac...
https://doi.org/10.1016/S1470-2045(21)00027-9
The Lancet. Oncology; Lamarca A, Palmer DH et. al.

Apr 2nd, 2021 - Advanced biliary tract cancer has a poor prognosis. Cisplatin and gemcitabine is the standard first-line chemotherapy regimen, but no robust evidence is available for second-line chemotherapy. The aim of this study was to determine the benefit der...

Role of adjuvant and neoadjuvant therapy for resectable biliary tract cancer.
https://doi.org/10.1080/17474124.2021.1911645
Expert Review of Gastroenterology & Hepatology; Nara S, Esaki M et. al.

Apr 1st, 2021 - Introduction: Although the safety of biliary tract cancer resection has improved over the years, the recurrence rate is still high, and the postoperative prognosis remains low after biliary tract cancer resection. Therefore, the development of eff...

see more →

Guidelines  3 results

Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline.
https://doi.org/10.1200/JCO.18.02178
Journal of Clinical Oncology : Official Journal of the Am... Shroff RT, Kennedy EB et. al.

Mar 11th, 2019 - To develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with resected biliary tract cancer. ASCO convened an Expert Panel to conduct a systematic review of the literature on adjuvant therapy for ...

Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline
http://ascopubs.org/doi/full/10.1200/JCO.18.02178

Mar 10th, 2019 - PURPOSE To develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with resected biliary tract cancer. METHODS ASCO convened an Expert Panel to conduct a systematic review of the literature on adju...

The role of endoscopy in the evaluation and treatment of patients with biliary neoplasia
https://www.asge.org/docs/default-source/education/practice_guidelines/doc-the-role-of-endoscopy-in-the-evaluation-and-treatment-of-patients-with-biliary-neoplasia.pdf?sfvrsn=6
Michelle A. Anderson

Dec 9th, 2012 - This document reviews the approach to the evaluation and treatment of the patient with suspected biliary neoplasia (Table 2). A discussion of the role of endoscopy for ampullary adenomas can be found in another ASGE document.

see more →

Clinicaltrials.gov  1,467 results

Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tr...
https://doi.org/10.1007/s10637-021-01098-2 10.1002/cncr.32803 10.1056/NEJMoa0908721 10.1038/sj.bjc.6605779 10.1002/jhbp.233 10.1007/s00280-007-0673-7 10.1007/s00280-013-2106-0 10.1007/s10637-010-9553-9 10.1093/jjco/hys102 10.1159/000226214 10.1038/bmt.2012.244 10.1038/sj.bjc.6603648 10.1093/jjco/hym116 10.1093/annonc/mdy282 10.1093/annonc/mdz402 10.1016/S1470-2045(19)30733-8
Investigational New Drugs; Inoue H, Todaka A et. al.

Apr 9th, 2021 - Background Combination therapy of gemcitabine with cisplatin (GC) is a standard first-line therapy for unresectable or recurrent biliary tract cancer (BTC). S-1 is often used as a second-line therapy in clinical practice, based on the results of s...

Comparison of Inflammation-based Prognostic Scores in Patients With Biliary Tract Cance...
https://doi.org/10.21873/anticanres.14987
Anticancer Research; Utsumi M, Kitada K et. al.

Apr 4th, 2021 - Inflammation-based prognostic scores are proven prognostic biomarkers in various cancers. This study aimed to identify a useful prognostic score for patients with biliary tract cancer (BTC) after surgical resection. This retrospective study recrui...

Prognosis of Primary Sclerosing Cholangitis According to Age of Onset.
https://doi.org/10.1002/jhbp.952
Journal of Hepato-biliary-pancreatic Sciences; Watanabe T, Nakai Y et. al.

Apr 3rd, 2021 - Liver failure and biliary tract cancer (BTC) are major life-threatening events in the clinical course of primary sclerosing cholangitis (PSC). Although these are competing events, they are typically evaluated as a composite prognostic endpoint. In...

Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary trac...
https://doi.org/10.1016/S1470-2045(21)00027-9
The Lancet. Oncology; Lamarca A, Palmer DH et. al.

Apr 2nd, 2021 - Advanced biliary tract cancer has a poor prognosis. Cisplatin and gemcitabine is the standard first-line chemotherapy regimen, but no robust evidence is available for second-line chemotherapy. The aim of this study was to determine the benefit der...

Role of adjuvant and neoadjuvant therapy for resectable biliary tract cancer.
https://doi.org/10.1080/17474124.2021.1911645
Expert Review of Gastroenterology & Hepatology; Nara S, Esaki M et. al.

Apr 1st, 2021 - Introduction: Although the safety of biliary tract cancer resection has improved over the years, the recurrence rate is still high, and the postoperative prognosis remains low after biliary tract cancer resection. Therefore, the development of eff...

see more →

News  43 results

Few Responses With New Combo in Biliary Tract Cancer
https://www.medscape.com/viewarticle/929940

May 4th, 2020 - Relapsed or refractory biliary tract cancers are rare, aggressive tumors with few treatment options and poor prognosis. Immunotherapy has been tried, but in contrast to many other tumor types, immune checkpoint inhibitors have shown little efficac...

Few Responses With New Combo in Biliary Tract Cancer
https://www.staging.medscape.com/viewarticle/929940

May 4th, 2020 - Relapsed or refractory biliary tract cancers are rare, aggressive tumors with few treatment options and poor prognosis. Immunotherapy has been tried, but in contrast to many other tumor types, immune checkpoint inhibitors have shown little efficac...

Fast Five Quiz: Cholangiocarcinoma Presentation and Diagnosis
https://reference.medscape.com/viewarticle/922403_1

Feb 19th, 2020 - Cancer of the bile duct, or cholangiocarcinoma, is a malignant neoplasm of the intrahepatic or extrahepatic biliary epithelium. It is the most common biliary tract cancer and the second most common primary hepatic cancer. Although its etiology is ...

Fast Five Quiz: Cholangiocarcinoma Presentation and Diagnosis
https://reference.medscape.com/viewarticle/922403

Feb 19th, 2020 - Cancer of the bile duct, or cholangiocarcinoma, is a malignant neoplasm of the intrahepatic or extrahepatic biliary epithelium. It is the most common biliary tract cancer and the second most common primary hepatic cancer. Although its etiology is ...

Aspirin Use Tied to Lower Risk of Death in Biliary Tract Cancer
https://www.medscape.com/viewarticle/920014

Oct 16th, 2019 - Patients with a rare and life-threatening form of gastrointestinal cancer might live longer if they are aspirin users, with the greatest effect seen in those who had not taken the drug before their cancer diagnosis, the results of a database analy...

see more →